First human tests begin for potential Alpha-1 treatment
NCT ID NCT06186492
Summary
This early-stage study tested the safety and how the body processes WVE-006, a potential new treatment for Alpha-1 antitrypsin deficiency. It involved 47 healthy volunteers who received either the drug or a placebo. The goal was to find safe dose levels to use in future studies with patients who have the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Simbec-Orion Clinical Pharmacology,
Merthyr Tydfil, Wales, CF48 4DR, United Kingdom
Conditions
Explore the condition pages connected to this study.